Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead Metabolic Disease Strategy
Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today announced three major milestones advancing its metabolic disease portfolio. The US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ENV-308, allowing Enveda to initiate a Phase 1 clinical study where the first participant was dosed last week.
Enveda Initiates Phase 2 Clinical Trials of ENV-294, a First-in-Class Oral Therapy in Atopic Dermatitis and Asthma
Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today announced that it has initiated two parallel Phase 2a clinical trials evaluating ENV-294, a first-in-class oral small molecule, for the treatment of moderate-to-severe Atopic Dermatitis (AD) and Asthma.
Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors
Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today announced three major milestones: the close of its $150 million oversubscribed Series D financing, enrolling of the first patient in a Phase 1b clinical trial for lead program ENV-294 in atopic dermatitis, and the appointment of former Pfizer Chief Scientific Officer and President of Worldwide R&D, Dr. Mikael Dolsten, to its Board of Directors.
Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis
Enveda, a clinical-stage biotechnology company pioneering the use of AI to unlock the therapeutic potential of life’s chemistry, today announced the successful completion of its Phase 1 clinical trial of ENV-294, a novel oral therapeutic for atopic dermatitis, asthma, and beyond. ENV-294 is a first-in-class anti-inflammatory small molecule derived from chemistry unearthed by Enveda’s platform. Based on the favorable safety and tolerability results in healthy volunteers, the Safety Review Committee endorsed advancement to a Phase 1b clinical trial evaluating ENV-294 in patients with atopic dermatitis.
Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M
Enveda, a leading biotechnology company harnessing life’s chemistry to discover better medicines, today announced an investment from Sanofi, a leading healthcare company. This investment reaffirms the industry’s confidence in Enveda’s groundbreaking drug discovery platform and its ability to deliver differentiated medicines. Sanofi’s addition to the Series C round builds on Enveda’s continued success in bringing novel therapeutics inspired by evolution from discovery to clinical trials.
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic, initially developed for atopic dermatitis, represents a breakthrough approach to respiratory inflammatory conditions. Enveda has assembled an advisory board comprising leading experts in asthma research and treatment to support this advancement.
Enveda Welcomes Jason Kim as Chief Financial Officer
Enveda, a biotechnology company using AI to translate life’s chemistry into new medicines, today announced the appointment of Jason Kim as Chief Financial Officer (CFO). Mr. Kim brings more than 20 years of biopharmaceutical corporate development and financial leadership experience to the Enveda team.
Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates
Enveda, a biotechnology company using AI to translate nature into new medicines, announced today an oversubscribed $130 million Series C funding round led by Kinnevik and FPV with participation from new and existing investors Baillie Gifford, Premji Invest, Lingotto Innovation, Lux Capital, Dimension Capital, True Ventures, Cresset Partners, The Nature Conservancy, and Henry R. Kravis. This brings the company's total funding to $360 million.
Enveda Announces First Candidate Discovered From Nature Using AI Advances to Clinical Trials
Enveda, a biotechnology company using AI to translate nature into new medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for its first asset targeting atopic dermatitis and other inflammatory conditions. The company also announced it has entered this candidate, named ENV-294, into a Phase I clinical trial, with the first patient dosed at the end of October.
